|
Blast Phase
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Imatinib, an ABL tyrosine kinase inhibitor, is dramatically effective in CML patients; however, 30% of CML patients will need further treatment due to progression of CML to blast crisis (BC).
|
27908728 |
2017 |
|
Blast Phase
|
0.100 |
Biomarker
|
disease |
BEFREE |
Patients in the chronic phase (CP) of chronic myelogenous leukemia (CML) have been treated successfully following the advent of ABL kinase inhibitors, but once they progress to the blast crisis (BC) phase the prognosis becomes dismal.
|
24098673 |
2013 |
|
Blast Phase
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
These results demonstrate that enhanced expression of p210BCR/ABL and deregulated expression of Zfp423/ZNF423 contribute to CML BC.
|
19234145 |
2009 |
|
Blast Phase
|
0.100 |
Biomarker
|
disease |
BEFREE |
These results indicate that Bcl11b and H2AX function as tumor suppressor and that haploinsufficiency and acquired loss of these gene products cooperate with p210BCR/ABL to develop CML BC.
|
19432895 |
2009 |
|
Blast Phase
|
0.100 |
Biomarker
|
disease |
BEFREE |
Chronic myelogenous leukemia (CML) is a hematopoietic disorder, which begins as indolent chronic phase but inevitably progresses to fatal blast crisis. p210BCR/ABL, a constitutively active tyrosine kinase, is responsible for disease initiation but molecular mechanism(s) underlying disease evolution remains largely unknown.
|
18193087 |
2008 |
|
Blast Phase
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party on Chronic Myeloid Leukemia.
|
15867198 |
2005 |
|
Blast Phase
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
These findings demonstrate that in late CP or advanced CML, ABL-kinase mutations occur as an intraclonal event in the primitive Ph1+ stem cell compartments with progression of this clone towards IM-resistant blast phase.
|
15381060 |
2004 |
|
Blast Phase
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In conclusion, patients with ABL deletions progress to blast crisis or accelerated phase in a significantly shorter time than do those without such deletions.
|
12759927 |
2003 |
|
Blast Phase
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
A point mutation leading to substitution at the ATP binding site of ABL-kinase and insensitivity to imatinib was detected in our patient treated with imatinib, who progressed to blast crisis.
|
12921956 |
2003 |
|
Blast Phase
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The arrest of differentiation is a feature of both chronic myelogenous leukemia cells in myeloid blast crisis and myeloid precursors that ectopically express the p210BCR-ABL oncoprotein; however, its underlying mechanisms remain poorly understood.
|
11753385 |
2002 |
|
Blast Phase
|
0.100 |
Biomarker
|
disease |
BEFREE |
The ataxia telangiectasia gene, ATM, is a candidate gene for this transformation because the complex karyotypes associated with BC of CML suggest that DNA double-strand break repair is defective and because the ABL pathway involves the interaction between the Abl and the Atm proteins.
|
11516106 |
2001 |
|
Blast Phase
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We report an at least 15-fold amplification of the ABL oncogene in a 29-year-old male patient with a variant Ph-positive t(19;22)(p13;q11.2) CML who presented in lymphoid blast crisis.
|
10190307 |
1999 |
|
Blast Phase
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Patients with CML in blast crisis, or with Philadelphia positive acute lymphoblastic leukaemia (ALL), can have a smaller BCR-ABL fusion transcript possessing only the first exon of BCR fused to ABL.
|
9858221 |
1998 |
|
Blast Phase
|
0.100 |
Biomarker
|
disease |
BEFREE |
In Philadelphia chromosome (Ph1)-positive leukemias such as chronic myelogenous leukemia (CML) and Ph1-positive acute lymphoblastic leukemia (ALL), both of which express bcr-abl fused gene products (P210bcr-abl or P190bcr-abl protein kinase) with augmented tyrosine kinase activities, herbimycin A markedly inhibited the in vitro growth of the Ph1-positive ALL cells and the leukemic cells derived from CML blast crisis.
|
1515646 |
1992 |
|
Blast Phase
|
0.100 |
Biomarker
|
disease |
BEFREE |
To investigate the hypothesis that the production of P190 may be associated with the progression from chronic phase to blast crisis in CML, we used polymerase chain reaction to analyze blood from 37 patients with accelerated phase/blast crisis CML for the transcripts coding for the P210BCR-ABL and P190BCR-ABL.
|
2013978 |
1991 |
|
Blast Phase
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In order to better define the relationship between type of genomic rearrangement, variant ABL protein expressed and haematological phenotype, a series of Ph1-positive acute leukaemias, both myeloblastic (AML) and lymphoblastic, and several CML lymphoid blast crises have been analysed at the DNA and protein level.
|
2223647 |
1990 |
|
Blast Phase
|
0.100 |
Biomarker
|
disease |
BEFREE |
The data suggest that the phl/abl protein product may influence the timing of the onset of blast crisis and imply a continuing role for this protein during the evolution of the disease.
|
2683759 |
1989 |
|
Blast Phase
|
0.100 |
Biomarker
|
disease |
BEFREE |
The aberrant abl protein product of a chronic myelogenous leukemia (CML) blast crisis cell line (K562) and of five Philadelphia chromosome-positive CML patients in blast crisis were analyzed by an immune complex kinase assay using two antipeptide sera generated against the hydrophilic domain of v-abl and a region within the third exon of the breakpoint cluster region (bcr) respectively.
|
2885048 |
1987 |